Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
VIVUS LLC
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06915246CT.gov A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma | — | Recruiting | — | — | — |
NCT03583424CT.gov Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT03019640CT.gov Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT03125642CT.gov Auto Stem Cell Transplant for Lymphoma Patients | — | Recruiting | — | — | — |
NCT02343666CT.gov HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection | — | Withdrawn | — | — | — |
NCT02797470CT.gov Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant | — | Active Not Recruiting | — | — | — |
NCT02059239CT.gov Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma | — | Completed | — | — | — |
NCT01969435CT.gov Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma | — | Completed | — | — | — |
NCT01840566CT.gov High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT01500161CT.gov Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match | — | Terminated | — | — | — |
Show 10 more trialsShow fewer
NCT00992446CT.gov Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT00712582CT.gov Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma | — | Completed | — | — | — |
NCT01148173CT.gov High-dose Chemotherapy and Stem Cell Transplantation for Central Nervous System (CNS) Relapse of Aggressive Lymphomas | — | Unknown | — | — | — |
NCT00481832CT.gov Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma | — | Terminated | — | — | — |
NCT00482053CT.gov Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT | — | Terminated | — | — | — |
NCT01220297CT.gov Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT | — | Terminated | — | — | — |
NCT00350181CT.gov Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT | — | Completed | — | — | — |
NCT00329030CT.gov Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) | — | Completed | — | — | — |
NCT00005803CT.gov Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma | — | Completed | — | — | — |
NCT00610883CT.gov LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Hodgkin Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Camustine (this asset) | VIVUS LLC | P3 | BB · 64 |
| Cyclosporin A | Memorial Sloan Kettering Cancer Center | P3 | BBB |
| Pegaspargase | Ciusss de L'Est de l'Île de Montréal | P4 | BBB |
| Adriamycin | National Cancer Institute (NCI) | P4 | BBB |
| Prednisolone | Mwanasha Merrill, MD | P3 | BBB |
| Entecavir | Fudan University | P4 | BBB |
| Cyclophosphamide | National Cancer Institute (NCI) | P4 | BBB |
| Rituximab | National Cancer Institute (NCI) | P4 | BBB |
| Prednisone | National Cancer Institute (NCI) | P3 | BBB |
+42 more in the Non-Hodgkin Lymphoma cohort
Other indications for Camustine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hodgkins Lymphoma | — | P2 | BBB · 74 |
| B-Cell Non-Hodgkin Lymphoma | — | P4 | BBB · 73 |
| Central Nervous System Neoplasm | — | P3 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Camustine in Non-Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/camustine-non-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →